Screener

Eligibility screening

A Phase II Trial of ACR-368 and Low Dose Gemcitabine for Head and Neck Squamous Cell Carcinoma

Sponsored by H. Lee Moffitt Cancer Center and Research InstituteStudy detailsClinicalTrials.gov

1 US site in FL

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.